You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,700,531

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,700,531

Title:	Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease
Abstract:	The present invention relates to a composition comprising metformin as an active ingredient for preventing or treating inflammatory bowel disease. The metformin compound or the metformin-etanercept (product name: Enbrel) composite according to the present invention may have excellent effects of maintaining the thickness of the small intestine and length of the large intestine normal, inhibiting or decreasing the activity of IL-17 and TNF-a, and promoting or increasing the activity of IFNr, and therefore can be effectively used as a pharmaceutical composition for preventing or treating autoimmune diseases including inflammatory bowel disease.
Inventor(s):	Cho; Mi-La (Seoul, KR), Lee; Seon-Yeong (Suwon-si, KR), Yang; Eun-Ji (Seoul, KR), Son; Hye-Jin (Seoul, KR), Kim; Eun-Kyung (Seoul, KR), Ryu; Jun-Geol (Taebaek-si, KR)
Assignee:	Catholic University Industry Academic Cooperation Foundation (Seoul, KR)
Application Number:	14/663,235
Patent Claims:	1. A method for treating inflammatory bowel disease, comprising administering to a subject having inflammatory bowel disease a therapeutically effective amount of a metformin compound of Formula 1 ##STR00002## or a pharmaceutically acceptable salt thereof, in combination with a TNF-.alpha. inhibitor, wherein the TNF-.alpha. inhibitor is Etanercept. 2. The method of claim 1, wherein the inflammatory bowel disease is selected from the group consisting of Crohn's disease, intestinal lesions concomitant with Behcet's disease, ulcerative colitis, hemorrhagic rectal ulcer, and pouchitis.

Details for Patent 9,700,531

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2032-09-21
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2032-09-21
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2032-09-21
Immunex Corporation	ENBREL	etanercept	Injection	103795	02/01/2007	⤷ Try a Trial	2032-09-21
Immunex Corporation	ENBREL MINI	etanercept	Injection	103795	09/14/2017	⤷ Try a Trial	2032-09-21
Immunex Corporation	ENBREL	etanercept	Injection	103795		⤷ Try a Trial	2032-09-21
Immunex Corporation	ENBREL	etanercept	Injection	103795	03/05/2020	⤷ Try a Trial	2032-09-21
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.